Ligand Pharmaceuticals (LGND) Liabilities and Shareholders Equity (2010 - 2026)

Ligand Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $1.5 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.5 billion, up 69.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 billion (up 50.42% YoY), and the FY2025 annual result was $1.6 billion, up 65.71% from the prior year.
• Liabilities and Shareholders Equity came in at $1.5 billion for Q1 2026 at Ligand Pharmaceuticals, down from $1.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.6 billion in Q4 2025 to a low of $758.1 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $941.8 million (2024), against an average of $1.0 billion.
• Across the five-year window, Liabilities and Shareholders Equity slumped 41.22% in 2022 and surged 69.21% in 2026, its largest moves.
• Ligand Pharmaceuticals' Liabilities and Shareholders Equity stood at $762.7 million in 2022, then gained by 3.22% to $787.2 million in 2023, then advanced by 19.63% to $941.8 million in 2024, then surged by 65.71% to $1.6 billion in 2025, then slipped by 1.83% to $1.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.